Generic placeholder image

Recent Patents on Drug Delivery & Formulation

Editor-in-Chief

ISSN (Print): 1872-2113
ISSN (Online): 2212-4039

Perspective

Patent Perspective on Orodispersible Films

Author(s): Suresh Gupta*, Tegginamath Pramod Kumar and Devegowda Vishakante Gowda

Volume 14 , Issue 2 , 2020

Page: [88 - 97] Pages: 10

DOI: 10.2174/1872211314666200904104022

Price: $65

Abstract

The traditional oral dosage forms (tablets, capsules, syrups, and elixirs) suffer from various disadvantages. They are pretty challenging to administer to patients with dysphagia, mucositis, and vomiting tendency. Therefore, gaining patient compliance using conventional dosage forms is highly cumbersome. One of the most transformative and innovative approaches to overcome such challenges is Orodispersible Films, a Novel Drug Delivery System. They are easy to consume, no need to chew or swallow and they do not even require water for consumption. Therefore, several drugs have been converted into orodispersible films to gain patient compliance. With the advent of these film formulations, new innovations are erupting and accordingly, companies in India are actively protecting them by filing ordinary patent applications in India and internationally under the Patent Cooperation Treaty. Patenting in India poses unique patentability challenges when compared with rest of the world. Nonetheless, meeting all the challenges and obtaining a valid patent not only help in recouping the cost involved in developing new drugs and its novel drug delivery systems but also helps in taking legal action against alleged infringers. This review article identifies key active Indian players in the domain of ODF based on their patent filings in India (and abroad) and also identifies the challenges they face to obtain a grant.

Keywords: Orodispersible film, oral thin film, formulation, patent, patient compliance orodispersible film, patient compliance.

« Previous
Graphical Abstract
[1]
Overview: The TRIPS Agreement, World Trade Organization; 1 Jan 1995. Available from:https://www.wto.org/english/tratop_e/trips_e/intel2_e.htm
[2]
Nanda A. The Patents Act 1970. (39 of 1970)
[3]
Rosen H, Abribat T. The rise and rise of drug delivery. Nat Rev Drug Discov 2005; 4(5): 381-5.
[http://dx.doi.org/10.1038/nrd1721] [PMID: 15864267]
[5]
Heinrich MP, Woertz C, Kleinebudde P, Breitkreutz J. J, Oro-mucosal Preparations European Pharmacopoeia Comission, Ed. european pharmacopoeia europ direct for the quality of med & healthcare (EDQM) 2018; 10(9): 1303-17.
[http://dx.doi.org/10.1517/17425247.2013.804058]
[6]
ASHE Chemical Ltd. New Impregnated or Coated Films. GB 1061557A (1964).
[7]
Dixit RP, Puthli SP. Oral strip technology: overview and future potential. J Control Release 2009; 139(2): 94-107.
[http://dx.doi.org/10.1016/j.jconrel.2009.06.014] [PMID: 19559740]
[8]
Sublingual and buccal film compositions. US Patent No 8,475,8322017. Jun 27
[9]
Robert W, Hai-quan M, Corinne K, Russell M. Orally dissolving thin films containing allergens and methods of making and use. US Patent 9539334 WO2013/173697
[10]
Vrbata P, Berka P, Stránská D, Doležal P, Musilová M, Čižinská L. Electrospun drug loaded membranes for sublingual administration of sumatriptan and naproxen. Int J Pharm 2013; 457(1): 168-76.
[http://dx.doi.org/10.1016/j.ijpharm.2013.08.085] [PMID: 24050988]
[11]
U – Shaped Oral Thin Film. WO 2019/207067 2019.
[12]
Lam JK, Xu Y, Worsley A, Wong IC. Oral transmucosal drug delivery for pediatric use. Adv Drug Deliv Rev 2014; 73: 50-62.
[http://dx.doi.org/10.1016/j.addr.2013.08.011] [PMID: 23999459]
[13]
Slavkova M, Breitkreutz J. Orodispersible drug formulations for children and elderly. Eur J Pharm Sci 2015; 75(March): 2-9.
[http://dx.doi.org/10.1016/j.ejps.2015.02.015] [PMID: 25736528]
[14]
Lindgren S, Janzon L. Prevalence of swallowing complaints and clinical findings among 50-79-year-old men and women in an urban population. Dysphagia 1991; 6(4): 187-92.
[http://dx.doi.org/10.1007/BF02493524] [PMID: 1778094]
[15]
Bala R, Pawar P, Khanna S, Arora S. Orally dissolving strips: A new approach to oral drug delivery system. Int J Pharm Investig 2013; 3(2): 67-76.
[http://dx.doi.org/10.4103/2230-973X.114897] [PMID: 24015378]
[16]
Wasilewska K, Winnicka K. How to assess orodispersible film quality? A review of applied methods and their modifications. Acta Pharm 2019; 69(2): 155-76.
[http://dx.doi.org/10.2478/acph-2019-0018] [PMID: 31259725]
[17]
De Caro V, Giandalia G, Siragusa MG, Sutera FM, Giannola LI. New prospective in treatment of Parkinson’s disease: studies on permeation of ropinirole through buccal mucosa. Int J Pharm 2012; 429(1-2): 78-83.
[http://dx.doi.org/10.1016/j.ijpharm.2012.03.022] [PMID: 22465630]
[18]
Seager H. Drug-delivery products and the Zydis fast-dissolving dosage form. J Pharm Pharmacol 1998; 50(4): 375-82.
[http://dx.doi.org/10.1111/j.2042-7158.1998.tb06876.x] [PMID: 9625481]
[19]
Visser JC, Woerdenbag HJ, Hanff LM, Frijlink HW. Personalized Medicine in Pediatrics: The Clinical Potential of Orodispersible Films. AAPS PharmSciTech 2017; 18(2): 267-72.
[http://dx.doi.org/10.1208/s12249-016-0515-1] [PMID: 27044380]
[20]
Yir-Erong B, Bayor MT, Ayensu I, Gbedema SY, Boateng JS. Oral thin films as a remedy for noncompliance in pediatric and geriatric patients. Ther Deliv 2019; 10(7): 443-64.
[http://dx.doi.org/10.4155/tde-2019-0032] [PMID: 31264527]
[21]
Hearnden V, Sankar V, Hull K. New developments and opportunities in oral mucosal drug delivery for local and systemic disease. Adv Drug Deliv Rev 2012; 64(1): 16-28.
[http://dx.doi.org/10.1016/j.addr.2011.02.008] [PMID: 21371513]
[22]
Gijare C, Deshpande A. Orodispersible Films: A systematic patent review. Recent Pat Drug Deliv Formul 2018; 12(2): 110-20.
[http://dx.doi.org/10.2174/1872211312666180509100216] [PMID: 29745346]
[23]
Gupta MS, Kumar TP. Characterization of Orodispersible Films: An Overview of Methods and Introduction to a New Disintegration Test Apparatus Using LDR - LED Sensors. J Pharm Sci 2020; S0022-3549(20): 30324-5.
[24]
Gupta MS, Kumar TP, Gowda DV, Film OT. A new patient-centered innovation. J Drug Deliv Sci Technol 2020; 59101843
[http://dx.doi.org/10.1016/j.jddst.2020.101843]
[25]
Borges AF, Silva C, Coelho JF, Simões S. Oral films: Current status and future perspectives II - Intellectual property, technologies and market needs. J Control Release 2015; 206: 108-21.
[http://dx.doi.org/10.1016/j.jconrel.2015.03.012] [PMID: 25776737]
[28]
Indian patent office, indian patent advanced search system [INPASS]. https://ipindiaservices.gov.in/publicsearch
[29]
World intellectual property office (wipo) ip portal. https://patentscope.wipo.int/search/en/search.jsf
[30]
Water soluble pharmaceutical film with enhanced stability. Indian Patent Application No 3221/MUM/2013 bearing pa-tent no 328544 (2013).
[31]
Process for the preparation of bi/multi-layer film, multi-layered film produced thereof and also apparatus for producing such multi-layer films Indian Patent Application No 201721035644
[32]
[33]
Trademark application number 1977594; Word mark for “THINORAL”. https://ipindiaonline.gov.in/eregister/eregister.aspx
[34]
Trademark application number 3750309; Word mark for “THINORALS”. https://ipindiaonline.gov.in/eregister/eregister.aspx
[35]
Improved Mucosal Delivery of Vitamin B12. Indian Patent Application No 2195/MUM/2015 2015.
[36]
Stable oral dispersible film of Ketorolac or its salts. Indian Patent Application No 2318/MUM/2015 2015.
[37]
Novel pharmaceutical dosages form, in particular, oral strip or thin film form of active cetirizine dihydrochloride through the novel process for manufacturing the same Indian Patent Application No 684/MUM/2007 2007.
[38]
Composition of active ingredient loaded edible ink and methods of making suitable substrates for active ingredient printing on orodispersible films. Indian Patent Application No 201821014188
[39]
Pharmaceutical micro-emulsion immobilized in a thin polymer matrix and methods of making them. Indian Patent Application No 3947/MUM/2013 2013.
[40]
Pharmaceutical Micro-emulsion Immobilized in a Thin Polymer Matrix And Methods of Making Them Indian Patent Application No 201627024411
[41]
Novel pharmaceutical dosages form, in particular, oral strip or thin film form of active cetirizine dihydrochloride through the novel process for manufacturing the same Indian Patent Application No 684/MUM/2007 (2007).
[42]
Novel pharmaceutical dosages form, in particular, oral strip or thin film form of active domperidone through the novel process for manufacturing the same Indian Patent Application No 685/MUM/2007 (2007).
[43]
Novel pharmaceutical dosages form, in particular oral strip or thin film form of active diclofenac sodium through the novel process for manufacturing the same. Indian Patent Application No 626/MUM/2007 2007.
[45]
Shilpa Therapeutics Limited. http://www.shilpatherapeutics.com/about/
[46]
Aavishkar Oral Strips Private Limited. http://www.aavishkar.com/products.html
[48]
Stabilized mouth freshener strips. 48) Indian Patent Application No 201641043542
[49]
Melatonin oral dissolving film Indian Patent Application No 201841011969
[50]
Oral dispersible film composition US Patent publication No 20190336453

Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy